BlackRock Advisors’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
$1.11M Buy
27,612
+776
+3% +$29.3K ﹤0.01% 1807
2016
Q3
$972K Buy
26,836
+2,455
+10% +$84.3K ﹤0.01% 1838
2016
Q2
$707K Buy
24,381
+589
+2% +$17.8K ﹤0.01% 1932
2016
Q1
$832K Buy
23,792
+1,434
+6% +$46.3K ﹤0.01% 1830
2015
Q4
$721K Sell
22,358
-10,316
-32% -$335K ﹤0.01% 1903
2015
Q3
$1.06M Sell
32,674
-1,426
-4% -$53.7K ﹤0.01% 1654
2015
Q2
$1.41M Buy
34,100
+1,341
+4% +$56.5K ﹤0.01% 1435
2015
Q1
$1.47M Buy
32,759
+4,794
+17% +$200K ﹤0.01% 1348
2014
Q4
$1.05M Sell
27,965
-1,315
-4% -$48.2K ﹤0.01% 1467
2014
Q3
$1.02M Sell
29,280
-556
-2% -$19.8K ﹤0.01% 1419
2014
Q2
$1.05M Sell
29,836
-46,170
-61% -$1.54M ﹤0.01% 1459
2014
Q1
$2.48M Buy
76,006
+43,165
+131% +$1.65M ﹤0.01% 1130
2013
Q4
$1.38M Buy
32,841
+2,182
+7% +$89.8K ﹤0.01% 1324
2013
Q3
$1.22M Sell
30,659
-214,639
-88% -$9.01M ﹤0.01% 1332
2013
Q2
$10.1M Buy
+245,298
New +$9.93M 0.01% 776

Other funds holding HAE

BlackRock Advisors's HAE Position: Q4 2016 in Review

BlackRock Advisors increased its Haemonetics (HAE) stake by 2.9% in Q4 2016, buying an estimated $29.3K and bringing the position to 27,612 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #1807.

BlackRock Advisors first reported a position in HAE in Q2 2013 and has held it in 15 quarters since. The position peaked at $10.1M in Q2 2013. 197 funds tracked by Wall St. Rank hold HAE as of Q4 2016.

  • BlackRock Advisors held 27,612 shares of Haemonetics worth $1.11M as of Q4 2016.
  • BlackRock Advisors bought 776 Haemonetics shares in Q4 2016, an estimated $29.3K.
  • Haemonetics made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1807 holding.
  • BlackRock Advisors first reported a position in Haemonetics in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Advisors's Haemonetics position peaked at $10.1M in Q2 2013.
  • 197 funds tracked by Wall St. Rank held Haemonetics as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.